In ATTR amyloidosis, the standard of care includes agents capable of stabilizing or knocking down liver synthesis of TTR, while treatment of AL amyloidosis is based on chemotherapy targeting the plasma cell clone [7, 8]. Here, TTR is linked to AL amyloidosis.